Spinal for Laparoscopic Cholecystectomy

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02768376

Acronym

Sp-Lap

Enrollment

Registered

2016-05-11

Start date

2016-03-31

Completion date

2017-10-31

Last updated

2016-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Laparoscopic Cholecystectomy

Brief summary

In this study, the investigators will study spinal anesthesia for laparoscopic cholecystectomy in comparison to general anesthesia (GA) regarding patient satisfaction as a primary variable, intraoperative complications, postoperative analgesic requirements, postoperative nausea and vomiting, patient hospital stay (secondary variables).

Interventions

DRUGBupivacaine with Fentanyl (Spinal Anesthesia)

Intrathecal injection of 15 mg Bupivacaine 0.5% at L 2-3 level mixed with 20 µ Fentanyl. Patients head will be lowered till sensory level of T 6 is abstained.

DRUGGeneral anesthesia

Induction by propofl 1.5-2 mg/kg, Fentanyl 1-2 mic/kg and atracrium 0.5 mg/kg Then maintained using Sevoflurane based anesthesia aiming to maintain Bispectral index 40-60..

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* patients scheduled for laparoscopic cholecystectomy

Exclusion criteria

* coagulopathy * Patient refusal * previous spine surgery * Obesity BMI more than 30

Design outcomes

Primary

Measure	Time frame
Patient satisfaction (over a scale from 1 to 4)	24 hours
Postoperative analgesic consumption (mg morphine)	24 hours

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026